secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2023-06-01T23:59:59+00:00
Accession:  0001213900-23-045091
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics amends Eisai license and corrects preferred stock exchange with 3i
--------------------------------------------------------------------------------

- Fourth Amendment with Eisai postpones $1.1M extension payment, with $850,000 due by March 1, 2024.
- Clinical trial enrollment deadline for Stenoparib extended to April 1, 2024; Eisai may terminate if not met.
- Amendment with 3i corrects Series C-to-Series A exchange from 4,027 to 5,577 shares of Series A Preferred Stock.
- Amended Certificate of Designations grants Series A holders voting rights on an as-converted basis and special board voting rights for reverse stock split proposal.
- Board's special voting rights for reverse stock split and adjournment expire on July 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390023045091/0001213900-23-045091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390023045091/ea179534-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-045091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer